The Impact of the International Cooperation On Familial
Hypercholesterolemia Screening and Treatment: Results from the
ScreenPro FH Project

J 2019

The Impact of the International Cooperation On Familial Hypercholesterolemia Screening and Treatment: Results from the ScreenPro FH Project

ČEŠKA, Richard, Gustavs LATKOVSKIS, Marat V. EZHOV, Tomáš FREIBERGER, Katarina LALIC et. al.

Basic information

Original name

The Impact of the International Cooperation On Familial Hypercholesterolemia Screening and Treatment: Results from the ScreenPro FH Project

Authors

ČEŠKA, Richard (guarantor), Gustavs LATKOVSKIS (428 Latvia), Marat V. EZHOV (643 Russian Federation), Tomáš FREIBERGER (203 Czech Republic, belonging to the institution), Katarina LALIC (688 Serbia), Olena MITCHENKO (804 Ukraine), Gyorgy PARAGH (348 Hungary), Zaneta PETRULIONIENE (440 Lithuania), Belma POJSKIC (70 Bosnia and Herzegovina), Katarina RASLOVA (703 Slovakia), Aleksandr B. SHEK (860 Uzbekistan), Branislav VOHNOUT (703 Slovakia), Tereza ALTSCHMIEDOVÁ (203 Czech Republic) and Veronika TODOROVOVÁ (203 Czech Republic)

Edition

CURRENT ATHEROSCLEROSIS REPORTS, PHILADELPHIA, CURRENT MEDICINE GROUP, 2019, 1523-3804

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30201 Cardiac and Cardiovascular systems

Country of publisher

United States of America

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 4.608

RIV identification code

RIV/00216224:14110/19:00110564

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.1007/s11883-019-0797-3

UT WoS

000472535400003

Keywords in English

Familial hypercholesterolemia; FH; ScreenPro FH; Evolocumab; Alirocumab; LDL-C

Abstract

V originále

Purpose of ReviewFamilial hypercholesterolemia (FH) is often perceived and described as underdiagnosed and undertreated, though effective treatment of FH is available. Owing to the mentioned facts, it is ever more imperative to screen and treat FH patients. Subsequent to the identification of patients, the project focuses on the improvement of their prognoses. The ScreenPro FH project was established as a functional international network for the diagnosis, screening, and treatment of FH. Individual countries were assigned goals, e.g., to define the actual situation and available treatment. With central support, more centers and countries participated in the project. Subsequently, individual countries reported the results at the beginning and end of the project. Collected data were statistically evaluated.Recent FindingsThe increasing number of patients in databases, from 7500 in 2014 to 25,347 in 2018, demonstrates the improvement in overall effectiveness, as well as an increase in the number of centers from 70 to 252. Before all, LDL-C decreased by 41.5% and total cholesterol by 32.3%. As data from all countries and patients were not available at the time of the analysis, only those results from 10 countries and 5585 patients at the beginning of the project and at the time of writing are included.SummaryOur data are quite positive. However, our results have only limited validity. Our patients are far from the target levels of LDL-C. The situation can be improved with the introduction of new therapy, PCSK9-i, evolocumab, and alirocumab. International cooperation improved the screening of FH and finally led to an improvement in cardiovascular risk.

Citovat

ČEŠKA, Richard, Gustavs LATKOVSKIS, Marat V. EZHOV, Tomáš FREIBERGER, Katarina LALIC, Olena MITCHENKO, Gyorgy PARAGH, Zaneta PETRULIONIENE, Belma POJSKIC, Katarina RASLOVA, Aleksandr B. SHEK, Branislav VOHNOUT, Tereza ALTSCHMIEDOVÁ and Veronika TODOROVOVÁ. The Impact of the International Cooperation On Familial Hypercholesterolemia Screening and Treatment: Results from the ScreenPro FH Project. CURRENT ATHEROSCLEROSIS REPORTS. PHILADELPHIA: CURRENT MEDICINE GROUP, 2019, vol. 21, No 9, p. 1-12. ISSN 1523-3804. Available from: https://dx.doi.org/10.1007/s11883-019-0797-3.

@article{1551982,
   author = {Češka, Richard and Latkovskis, Gustavs and Ezhov, Marat V. and Freiberger, Tomáš and Lalic, Katarina and Mitchenko, Olena and Paragh, Gyorgy and Petrulioniene, Zaneta and Pojskic, Belma and Raslova, Katarina and Shek, Aleksandr B. and Vohnout, Branislav and Altschmiedová, Tereza and Todorovová, Veronika},
   article_location = {PHILADELPHIA},
   article_number = {9},
   doi = {http://dx.doi.org/10.1007/s11883-019-0797-3},
   keywords = {Familial hypercholesterolemia; FH; ScreenPro FH; Evolocumab; Alirocumab; LDL-C},
   language = {eng},
   issn = {1523-3804},
   journal = {CURRENT ATHEROSCLEROSIS REPORTS},
   title = {The Impact of the International Cooperation On Familial Hypercholesterolemia Screening and Treatment: Results from the ScreenPro FH Project},
   url = {http://dx.doi.org/10.1007/s11883-019-0797-3},
   volume = {21},
   year = {2019}
}

TY  - JOUR
ID  - 1551982
AU  - Češka, Richard - Latkovskis, Gustavs - Ezhov, Marat V. - Freiberger, Tomáš - Lalic, Katarina - Mitchenko, Olena - Paragh, Gyorgy - Petrulioniene, Zaneta - Pojskic, Belma - Raslova, Katarina - Shek, Aleksandr B. - Vohnout, Branislav - Altschmiedová, Tereza - Todorovová, Veronika
PY  - 2019
TI  - The Impact of the International Cooperation On Familial Hypercholesterolemia Screening and Treatment: Results from the ScreenPro FH Project
JF  - CURRENT ATHEROSCLEROSIS REPORTS
VL  - 21
IS  - 9
SP  - 1-12
EP  - 1-12
PB  - CURRENT MEDICINE GROUP
SN  - 15233804
KW  - Familial hypercholesterolemia
KW  - FH
KW  - ScreenPro FH
KW  - Evolocumab
KW  - Alirocumab
KW  - LDL-C
UR  - http://dx.doi.org/10.1007/s11883-019-0797-3
L2  - http://dx.doi.org/10.1007/s11883-019-0797-3
N2  - Purpose of ReviewFamilial hypercholesterolemia (FH) is often perceived and described as underdiagnosed and undertreated, though effective treatment of FH is available. Owing to the mentioned facts, it is ever more imperative to screen and treat FH patients. Subsequent to the identification of patients, the project focuses on the improvement of their prognoses. The ScreenPro FH project was established as a functional international network for the diagnosis, screening, and treatment of FH. Individual countries were assigned goals, e.g., to define the actual situation and available treatment. With central support, more centers and countries participated in the project. Subsequently, individual countries reported the results at the beginning and end of the project. Collected data were statistically evaluated.Recent FindingsThe increasing number of patients in databases, from 7500 in 2014 to 25,347 in 2018, demonstrates the improvement in overall effectiveness, as well as an increase in the number of centers from 70 to 252. Before all, LDL-C decreased by 41.5% and total cholesterol by 32.3%. As data from all countries and patients were not available at the time of the analysis, only those results from 10 countries and 5585 patients at the beginning of the project and at the time of writing are included.SummaryOur data are quite positive. However, our results have only limited validity. Our patients are far from the target levels of LDL-C. The situation can be improved with the introduction of new therapy, PCSK9-i, evolocumab, and alirocumab. International cooperation improved the screening of FH and finally led to an improvement in cardiovascular risk.
ER  -

ČEŠKA, Richard, Gustavs LATKOVSKIS, Marat V. EZHOV, Tomáš FREIBERGER, Katarina LALIC, Olena MITCHENKO, Gyorgy PARAGH, Zaneta PETRULIONIENE, Belma POJSKIC, Katarina RASLOVA, Aleksandr B. SHEK, Branislav VOHNOUT, Tereza ALTSCHMIEDOVÁ and Veronika TODOROVOVÁ. The Impact of the International Cooperation On Familial Hypercholesterolemia Screening and Treatment: Results from the ScreenPro FH Project. \textit{CURRENT ATHEROSCLEROSIS REPORTS}. PHILADELPHIA: CURRENT MEDICINE GROUP, 2019, vol.~21, No~9, p.~1-12. ISSN~1523-3804. Available from: https://dx.doi.org/10.1007/s11883-019-0797-3.

Detailed Information on Publication Record